Paving The Way For Regulated FIP Treatment in Canada

In 2022, Dr. Jeff Aramini designed and conducted a groundbreaking case series study in Canada focused on making Feline Infectious Peritonitis (FIP) treatment more accessible, affordable, and clinically consistent for veterinarians and pet families alike.

At a time when GS-441524 was not yet readily available to veterinarians in North America, this study utilized research-quality oral medications, compounded at a pharmacy in Ontario and overseen by a Licensed Ontario DMV. The goal was clear: reduce barriers to treatment while maintaining rigorous clinical oversight.

Between November 2022 and April 2025, Dr. Aramini treated over 600 confirmed FIP cases, all following the same standardized protocol combining GS-441524 and Mefloquine to limit resistance, relapses, and treatment failure.

This webinar offers a firsthand look at the clinical insights, outcomes, and lessons learned from this unprecedented body of work.

Every case in this study followed a consistent, evidence-informed approach designed to optimize outcomes while minimizing risk.

By combining GS-441524 with Mefloquine, the protocol aimed to address known challenges such as viral resistance and relapse, while remaining practical for real-world veterinary use.

During this session, Dr. Aramini will walk through:

• The rationale behind protocol design
• Observed clinical responses and outcomes
• Practical considerations for early diagnosis and treatment initiation
• The role of supportive therapies in improving treatment success

This is a rare opportunity to explore how large-scale, real-world data can inform daily clinical decision-making.

By the end of this session, participants will be able to:

• Recognize the significance of using response to GS-441524 as a diagnostic indicator for FIP
• Understand why initiating GS-441524 treatment as early as a tentative diagnosis is critical
• Apply proper and consistent dosing of GS-441524 and Mefloquine to ensure therapeutic effectiveness
• Identify key supportive treatments essential to successful outcomes, particularly during the early phases of therapy

Dr. Jeff Aramini

President, co-founder and medical director at PetNation, veterinary innovator, clinical research leader.

Dr. Aramini has been at the forefront of advancing regulated FIP treatment in Canada. His work bridges clinical research and practical application, with a focus on improving access to life-saving therapies while maintaining professional oversight and patient safety.